Jennifer Cultrera, MD
Medical Oncology · Lady Lake, FLNPI 1316041064
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Amgen at 31.5% of the total. Reporting peaked in 2019 at $29,229 and has fallen 93.9% since, to $1,798 in 2025.
Across 749 payments — averaging $60.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$14K
- Bristol Myers Squibb$9K
- Aurobindo Pharma USA, Inc.$7K
- Verastem, Inc.$4K
- Johnson & Johnson$1K
- Novartis$878
- plus $10K from 54 others
Across 1,211 payments — averaging $7547.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$5.2M
- Novartis$856K
- TG Therapeutics, Inc.$720K
- Acerta Pharma LLC$480K
- Eli Lilly$369K
- Takeda Pharmaceuticals U.S.A., Inc.$236K
- plus $1.3M from 15 others
What the payments were for
- Consulting fees$5,46012%
- Speaking & faculty fees$23,03050%
- Travel & lodging$3,1627%
- Food & beverage$13,57330%
- Education$4101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,634 in reported general payments places this provider in the 80th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 82 | $1,463,493 |
| ImbruvicaIbrutinib | 34 | $526,594 |
| JakafiRuxolitinib Phosphate | 24 | $419,563 |
| IbrancePalbociclib | 26 | $397,866 |
| BrukinsaZanubrutinib | 19 | $278,694 |
| EliquisApixaban | 129 | $159,959 |
| GilotrifAfatinib Dimaleate | 11 | $126,569 |
| XareltoRivaroxaban | 28 | $44,024 |
| Anastrozole | 350 | $6,114 |
| Exemestane | 32 | $4,649 |
| Ondansetron Hcl | 16 | $4,074 |
| Atovaquone | 12 | $2,767 |
| Letrozole | 75 | $2,606 |
| Prochlorperazine Maleate | 46 | $1,368 |
| Hydroxyurea | 39 | $1,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $8,618 | $1,463,49382 claims |
| PfizerIbrance, Eliquis | $490 | $557,825155 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $264 | $526,59434 claims |
| Incyte CorporationJakafi | $319 | $419,56324 claims |
| Beigene USA, Inc.Brukinsa | $264 | $278,69419 claims |
| Boehringer IngelheimGilotrif | $85 | $126,56911 claims |
| Johnson & JohnsonXarelto | $1,091 | $44,02428 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $35 | $1,20655 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Lady Lake
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.